{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:46:12Z","timestamp":1783784772783,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jiangsu Province Traditional Chinese medicine science and technology development program","award":["YB2020094"],"award-info":[{"award-number":["YB2020094"]}]},{"name":"Suqian Science and Technology Program","award":["K202324"],"award-info":[{"award-number":["K202324"]}]},{"name":"Xuzhou Medical University Affiliated Hospital Science and Technology Development Funding","award":["XYFM2241"],"award-info":[{"award-number":["XYFM2241"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Bladder cancer (BC) is notably prevalent, particularly among men. Emerging evidence highlights that traditional Chinese medicine (TCM) has distinct anticancer properties. This study focuses on recombinant MAP30, a key active constituent of<jats:italic> Momordica charantia<\/jats:italic> extract, recognized for its antiviral, immunomodulatory, and antitumor effects. We discovered that MAP30 suppresses BC cell proliferation and induces apoptosis in a dose-responsive manner. It also hinders cell migration, as evidenced by Transwell and wound healing assays. In nude mice, MAP30 injections adjacent to tumors significantly curtail tumor growth. Molecular analyses after MAP30 exposure show elevated SA-\u03b2-Gal activity and increased expression of cell cycle inhibitors p21 and p16 in BC cells. Integrating TCGA BC data, MAP30 appears to correct dysregulated gene expression associated with the cell cycle, senescence, apoptosis, and key pathways such as FOXO, TNF, and MAPK. Proteomic analysis identifies CENPA as a central molecule inhibited by MAP30. Correlation studies reveal CENPA\u2019s significant association with oncogenic and immune-modulatory gene expression and immune cell infiltration. CENPA knockdown diminishes BC cell growth and motility, while its overexpression in MAP30-treated cells reverses these effects, suggesting CENPA\u2019s pivotal role in MAP30\u2019s anticancer activity and its potential as a therapeutic target. In conclusion, recombinant MAP30 effectively hampers bladder cancer cell proliferation and migration via CENPA downregulation and induces apoptosis and senescence, offering therapeutic potential against bladder cancer.<\/jats:p>","DOI":"10.1038\/s41598-025-14977-y","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T11:48:38Z","timestamp":1755085718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Suppressive effects of Momordica charantia MAP30 on the senescence, proliferation and migration of bladder cancer cells mediated by CENPA"],"prefix":"10.1038","volume":"15","author":[{"given":"Kun","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longjun","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"issue":"1","key":"14977_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","volume":"71","author":"S Antoni","year":"2017","unstructured":"Antoni, S. et al. Bladder cancer incidence and mortality: A global overview and recent trends. Eur. Urol. 71 (1), 96\u2013108. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.010 (2017). Epub 2016\/07\/03.","journal-title":"Eur. Urol."},{"key":"14977_CR2","doi-asserted-by":"publisher","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E., Jemal, A. & Cancer Statistics CA Cancer J Clin  72 (1) 7\u201333. (2022). https:\/\/doi.org\/10.3322\/caac.21708","DOI":"10.3322\/caac.21708"},{"issue":"10364","key":"14977_CR3","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/s0140-6736(22)01188-6","volume":"400","author":"E Comp\u00e9rat","year":"2022","unstructured":"Comp\u00e9rat, E. et al. Current best practice for bladder cancer: A narrative review of diagnostics and treatments. Lancet 400 (10364), 1712\u20131721. https:\/\/doi.org\/10.1016\/s0140-6736(22)01188-6 (2022). Epub 2022\/09\/30.","journal-title":"Lancet"},{"issue":"5","key":"14977_CR4","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1142\/S0192415x18500507","volume":"46","author":"SM Wang","year":"2018","unstructured":"Wang, S. M., Long, S. Q. & Wu, W. Y. Application of traditional Chinese medicines as personalized therapy in human cancers. Am. J. Chin. Med. 46 (5), 953\u2013970. https:\/\/doi.org\/10.1142\/S0192415x18500507 (2018).","journal-title":"Am. J. Chin. Med."},{"issue":"5","key":"14977_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2174\/1386207320666170116141818","volume":"20","author":"ZK Yan","year":"2017","unstructured":"Yan, Z. K., Lai, Z. J. & Lin, J. M. Anticancer properties of traditional Chinese medicine. Comb. Chem. High. T Scr. 20 (5), 423\u2013429. https:\/\/doi.org\/10.2174\/1386207320666170116141818 (2017).","journal-title":"Comb. Chem. High. T Scr."},{"issue":"11","key":"14977_CR6","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1055\/s-0030-1250186","volume":"76","author":"WL Hsiao","year":"2010","unstructured":"Hsiao, W. L. & Liu, L. The role of traditional Chinese herbal medicines in cancer Therapy\u2013from Tcm theory to mechanistic insights. Planta Med. 76 (11), 1118\u20131131. https:\/\/doi.org\/10.1055\/s-0030-1250186 (2010).","journal-title":"Planta Med."},{"key":"14977_CR7","doi-asserted-by":"publisher","first-page":"105728","DOI":"10.1016\/j.phrs.2021.105728","volume":"170","author":"S Wang","year":"2021","unstructured":"Wang, S. et al. Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy. Pharmacol. Res. 170, 105728. https:\/\/doi.org\/10.1016\/j.phrs.2021.105728 (2021).","journal-title":"Pharmacol. Res."},{"issue":"4","key":"14977_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/s1875-5364(14)60050-9","volume":"12","author":"WY Wu","year":"2014","unstructured":"Wu, W. Y. et al. Tcm-Based new drug discovery and development in China. Chin. J. Nat. Med. 12 (4), 241\u2013250. https:\/\/doi.org\/10.1016\/s1875-5364(14)60050-9 (2014).","journal-title":"Chin. J. Nat. Med."},{"key":"14977_CR9","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2018.3","author":"J Wang","year":"2018","unstructured":"Wang, J., Wong, Y-K. & Liao, F. What has traditional Chinese medicine delivered for modern medicine? Expert Rev. Mol. Med. https:\/\/doi.org\/10.1017\/erm.2018.3 (2018)."},{"issue":"5","key":"14977_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2174\/156652411795976583","volume":"11","author":"EF Fang","year":"2011","unstructured":"Fang, E. F. & Ng, T. B. Bitter gourd (Momordica charantia) is a cornucopia of health: A review of its credited antidiabetic, Anti-Hiv, and antitumor properties. Curr. Mol. Med. 11 (5), 417\u2013436 (2011).","journal-title":"Curr. Mol. Med."},{"issue":"3","key":"14977_CR11","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1177\/1534735415611747","volume":"15","author":"MMH Yung","year":"2016","unstructured":"Yung, M. M. H. et al. Bitter melon (Momordica charantia) extract inhibits tumorigenicity and overcomes Cisplatin-Resistance in ovarian cancer cells through targeting Ampk signaling cascade. Integr. Cancer Ther. 15 (3), 376\u2013389. https:\/\/doi.org\/10.1177\/1534735415611747 (2016).","journal-title":"Integr. Cancer Ther."},{"issue":"2","key":"14977_CR12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1006\/bbrc.1995.1405","volume":"208","author":"AS Bourinbaiar","year":"1995","unstructured":"Bourinbaiar, A. S. & Lee-Huang, S. Potentiation of Anti-Hiv activity of Anti-Inflammatory drugs, dexamethasone and indomethacin, by Map30, the antiviral agent from bitter melon. Biochem. Biophys. Res. Commun. 208 (2), 779\u2013785. https:\/\/doi.org\/10.1006\/bbrc.1995.1405 (1995).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"14977_CR13","doi-asserted-by":"publisher","first-page":"105157","DOI":"10.1016\/j.phrs.2020.105157","volume":"161","author":"DW Chan","year":"2020","unstructured":"Chan, D. W. et al. Map30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis. Pharmacol. Res. 161, 105157. https:\/\/doi.org\/10.1016\/j.phrs.2020.105157 (2020).","journal-title":"Pharmacol. Res."},{"issue":"4","key":"14977_CR14","doi-asserted-by":"publisher","first-page":"5833","DOI":"10.3892\/ol.2018.8073","volume":"15","author":"Y Jiang","year":"2018","unstructured":"Jiang, Y. et al. Map30 promotes apoptosis of U251 and U87 cells by suppressing the Lgr5 and Wnt\/\u0392-Catenin signaling pathway, and enhancing Smac expression. Oncol. Lett. 15 (4), 5833\u20135840. https:\/\/doi.org\/10.3892\/ol.2018.8073 (2018).","journal-title":"Oncol. Lett."},{"issue":"1","key":"14977_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12033-008-9034-y","volume":"39","author":"JM Fan","year":"2008","unstructured":"Fan, J. M. et al. Effects of Recombinant Map30 on cell proliferation and apoptosis of human colorectal carcinoma Lovo cells. Mol. Biotechnol. 39 (1), 79\u201386. https:\/\/doi.org\/10.1007\/s12033-008-9034-y (2008).","journal-title":"Mol. Biotechnol."},{"key":"14977_CR16","doi-asserted-by":"publisher","unstructured":"Zhou, Y. et al. Ribosome-inactivating protein Map30 isolated fromMomordica charantia L. Induces Apoptosis in hepatocellular Carcinoma cells. Recent Pat Anticancer Drug Discov (2022). https:\/\/doi.org\/10.2174\/1574892818666221103114649","DOI":"10.2174\/1574892818666221103114649"},{"issue":"D1","key":"14977_CR17","doi-asserted-by":"publisher","first-page":"D1023","DOI":"10.1093\/nar\/gkv1268","volume":"44","author":"M Zhao","year":"2016","unstructured":"Zhao, M., Kim, P., Mitra, R., Zhao, J. & Zhao, Z. Tsgene 2.0: an updated Literature-Based knowledgebase for tumor suppressor genes. Nucleic Acids Res. 44 (D1), D1023\u2013D1031. https:\/\/doi.org\/10.1093\/nar\/gkv1268 (2016).","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"14977_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong, P. et al. Pan-Cancer Immunogenomic analyses reveal Genotype-Immunophenotype relationships and predictors of response to checkpoint Blockade. Cell. Rep. 18 (1), 248\u2013262. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.019 (2017).","journal-title":"Cell. Rep."},{"issue":"3","key":"14977_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1142\/S0192415X09006941","volume":"37","author":"S Xutian","year":"2009","unstructured":"Xutian, S., Zhang, J. & Louise, W. New exploration and Understanding of traditional Chinese medicine. Am. J. Chin. Med. 37 (3), 411\u2013426. https:\/\/doi.org\/10.1142\/S0192415X09006941 (2009).","journal-title":"Am. J. Chin. Med."},{"issue":"3","key":"14977_CR20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1142\/S0192415X14500359","volume":"42","author":"CY Wang","year":"2014","unstructured":"Wang, C. Y., Bai, X. Y. & Wang, C. H. Traditional Chinese medicine: A treasured natural resource of anticancer drug research and development. Am. J. Chin. Med. 42 (3), 543\u2013559. https:\/\/doi.org\/10.1142\/S0192415X14500359 (2014).","journal-title":"Am. J. Chin. Med."},{"key":"14977_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/496169","author":"MA Alam","year":"2015","unstructured":"Alam, M. A. et al. Beneficial role of bitter melon supplementation in obesity and related complications in metabolic syndrome. J. Lipids. https:\/\/doi.org\/10.1155\/2015\/496169 (2015).","journal-title":"J. Lipids"},{"key":"14977_CR22","doi-asserted-by":"publisher","first-page":"1072376","DOI":"10.3389\/fimmu.2022.1072376","volume":"13","author":"Y Bao","year":"2022","unstructured":"Bao, Y., Han, X., Liu, D., Tan, Z. & Deng, Y. Gut microbiota: the key to the treatment of metabolic syndrome in traditional Chinese Medicine - a case study of diabetes and nonalcoholic fatty liver disease. Front. Immunol. 13, 1072376. https:\/\/doi.org\/10.3389\/fimmu.2022.1072376 (2022).","journal-title":"Front. Immunol."},{"issue":"2","key":"14977_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2174\/187153008784534330","volume":"8","author":"J Yin","year":"2008","unstructured":"Yin, J., Zhang, H. & Ye, J. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr. Metab. Immune Disord Drug Targets. 8 (2), 99\u2013111. https:\/\/doi.org\/10.2174\/187153008784534330 (2008).","journal-title":"Endocr. Metab. Immune Disord Drug Targets"},{"issue":"3","key":"14977_CR24","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1177\/1534735415611747","volume":"15","author":"MM Yung","year":"2016","unstructured":"Yung, M. M. et al. Bitter melon (Momordica charantia) extract inhibits tumorigenicity and overcomes Cisplatin-Resistance in ovarian cancer cells through targeting Ampk signaling cascade. Integr. Cancer Ther. 15 (3), 376\u2013389. https:\/\/doi.org\/10.1177\/1534735415611747 (2016).","journal-title":"Integr. Cancer Ther."},{"issue":"4","key":"14977_CR25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s11418-017-1099-0","volume":"71","author":"P Pitchakarn","year":"2017","unstructured":"Pitchakarn, P. et al. Kuguacin J isolated from bitter melon leaves modulates Paclitaxel sensitivity in Drug-Resistant human ovarian cancer cells. J. Nat. Med. 71 (4), 693\u2013702. https:\/\/doi.org\/10.1007\/s11418-017-1099-0 (2017).","journal-title":"J. Nat. Med."},{"key":"14977_CR26","doi-asserted-by":"publisher","first-page":"33532","DOI":"10.1038\/srep33532","volume":"6","author":"VP Dia","year":"2016","unstructured":"Dia, V. P. & Krishnan, H. B. Bg-4, a novel anticancer peptide from bitter gourd (Momordica charantia), Promotes Apoptosis in Human Colon Cancer Cells. Sci. Rep. 6, 33532. https:\/\/doi.org\/10.1038\/srep33532 (2016).","journal-title":"Sci. Rep."},{"issue":"4","key":"14977_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10495-011-0684-z","volume":"17","author":"EF Fang","year":"2012","unstructured":"Fang, E. F., Zhang, C. Z., Fong, W. P. & Ng, T. B. Rnase Mc2: A new Momordica charantia ribonuclease that induces apoptosis in breast cancer cells associated with activation of Mapks and induction of caspase pathways. Apoptosis 17 (4), 377\u2013387. https:\/\/doi.org\/10.1007\/s10495-011-0684-z (2012).","journal-title":"Apoptosis"},{"issue":"3","key":"14977_CR28","first-page":"275","volume":"68","author":"H Hlin","year":"2016","unstructured":"Hlin, H. et al. Expression of Momordica charantia Map30 and its antitumor effect on bladder cancer cells. Minerva Urol. Nefrol. 68 (3), 275\u2013281 (2016).","journal-title":"Minerva Urol. Nefrol"},{"issue":"4","key":"14977_CR29","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","volume":"179","author":"V Gorgoulis","year":"2019","unstructured":"Gorgoulis, V. et al. Cellular senescence: defining a path forward. Cell 179 (4), 813\u2013827. https:\/\/doi.org\/10.1016\/j.cell.2019.10.005 (2019).","journal-title":"Cell"},{"key":"14977_CR30","doi-asserted-by":"publisher","first-page":"14532","DOI":"10.1038\/ncomms14532","volume":"8","author":"MJ Schafer","year":"2017","unstructured":"Schafer, M. J. et al. Cellular senescence mediates fibrotic pulmonary disease. Nat. Commun. 8, 14532. https:\/\/doi.org\/10.1038\/ncomms14532 (2017).","journal-title":"Nat. Commun."},{"key":"14977_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.canlet.2018.03.043","volume":"425","author":"WT Liu","year":"2018","unstructured":"Liu, W. T. et al. A novel strategy of integrated microarray analysis identifies cenpa, Cdk1 and Cdc20 as a cluster of diagnostic biomarkers in lung adenocarcinoma. Cancer Lett. 425, 43\u201353. https:\/\/doi.org\/10.1016\/j.canlet.2018.03.043 (2018).","journal-title":"Cancer Lett."},{"issue":"5","key":"14977_CR32","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1101\/gad.290924.116","volume":"31","author":"D Filipescu","year":"2017","unstructured":"Filipescu, D. et al. Essential role for centromeric factors following P53 loss and oncogenic transformation. Genes Dev. 31 (5), 463\u2013480. https:\/\/doi.org\/10.1101\/gad.290924.116 (2017).","journal-title":"Genes Dev."},{"issue":"4","key":"14977_CR33","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.molcel.2014.01.018","volume":"53","author":"N Lacoste","year":"2014","unstructured":"Lacoste, N. et al. Mislocalization of the centromeric histone variant Cenh3\/Cenp-a in human cells depends on the chaperone Daxx. Mol. Cell. 53 (4), 631\u2013644. https:\/\/doi.org\/10.1016\/j.molcel.2014.01.018 (2014).","journal-title":"Mol. Cell."},{"issue":"16","key":"14977_CR34","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.7150\/ijbs.85656","volume":"19","author":"J Liao","year":"2023","unstructured":"Liao, J. et al. Cenpa functions as a transcriptional regulator to promote hepatocellular carcinoma progression via cooperating with Yy1. Int. J. Biol. Sci. 19 (16), 5218\u20135232. https:\/\/doi.org\/10.7150\/ijbs.85656 (2023).","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"14977_CR35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1186\/s12967-021-03087-8","volume":"19","author":"Q Wang","year":"2021","unstructured":"Wang, Q. et al. Cenpa promotes clear cell renal cell carcinoma progression and metastasis via Wnt\/\u0392-Catenin signaling pathway. J. Transl Med. 19 (1), 417. https:\/\/doi.org\/10.1186\/s12967-021-03087-8 (2021).","journal-title":"J. Transl Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14977-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14977-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14977-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T18:17:27Z","timestamp":1759169847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-14977-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14977"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-14977-y","relation":{"references":[{"id-type":"doi","id":"10.1017\/erm.2018.3","asserted-by":"subject"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"25 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this Article was revised: The original version of this Article contained an error in Affiliation 1, which was incorrectly given as \u2018Department of Oncology, Suqian Hospital of Nanjing Drum Tower Hospital Group, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, China.\u2019 Additionally, Affiliation 2 was incorrectly given as \u2018Department of Urology, Suqian Hospital of Nanjing Drum Tower Hospital Group, The Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, China.\u2019 The correct affiliations are: 1. \u2018Department of Oncology, the Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, China.\u2019 and 2. \u2018Department of Urology, the Affiliated Suqian Hospital of Xuzhou Medical University, Suqian, China.\u2019 The original Article has been corrected.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The animal protocol was approved by the Laboratory Animal Ethics Committee of the Experimental Animal Center of the Soochow University (approval no. 202011A070). All animals were cared for following the National Institutes of Health Guide for the Care and Use of Laboratory Animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}}],"article-number":"29679"}}